FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-02									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Brazzell Romulus K					Ka	2. Issuer Name and Ticker or Trading Symbol Kala Pharmaceuticals, Inc. [ KALA ]								(Che	eck all applic Directo	able)	10% Own		vner	
	ast) (First) (Middle) /O KALA PHARMACEUTICALS, INC. 90 ARSENAL WAY, SUITE 210					3. Date of Earliest Transaction (Month/Day/Year) 04/09/2020									C	Chief Med	lical	Officer		
(Street) WATER	reet) VATERTOWN MA 02472				4. II	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City)	(S		(Zip)																	
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/L						action Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Sec Transaction Dispo Code (Instr. 5)			ired (		5. Amou Securitie Benefici	nt of	Form (D) o	n: Direct or Indirect	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)		Price	Reported Transact (Instr. 3	ion(s)			(Instr. 4)	
Common Stock 04				04/09	9/2020				М		1,880	0 .	A	\$0.68	110	),605		D		
Common Stock 04/				04/09	9/2020				М		18,24	7 .	1	\$2.3	128	,852		D		
Common	Common Stock			04/09	04/09/2020				М		47,64	4 .	A	\$3.34	176	5,496		D		
		-	Table II - I						uired, D s, option						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution E if any (Month/Day	Date, T	4. Transaction Code (Instr. 8)				6. Date Exercisa Expiration Date (Month/Day/Yea		•	7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				C	code	ode V		(D)	Date Exercisab		Expiration Date	Title	or Nu of	ımber						
Stock Option (right to buy)	\$0.68	04/09/2020			М			1,880	(1)	C	05/09/2023	Commo Stock	n 1	,880	\$0.00	0		D		
Stock Option (right to buy)	\$2.3	04/09/2020			М			18,247	(2)	1	10/01/2021	Commo Stock	n 18	3,247	\$0.00	0		D		
Stock Option (right to	\$3.34	04/09/2020			M			47,644	(3)	C	06/16/2026	Commo	n 47	7,677	\$0.00	13,508	8	D		

## Explanation of Responses:

- 1. The option became fully vested on December 31, 2017.
- 2. The option became fully vested on September 25, 2018.
- 3. This option was granted on June 17, 2016 and vests over four years, with 25% of the shares underlying the option vesting on June 17, 2017 and an additional 2.0833% vesting at the end of each successive one-month period thereafter.

/s/ Eric Trachtenberg, Attorneyin-Fact 04/13/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.